State of the Science Summit on Treatment Options in Ovarian Cancer | Conference

Dr. Sabbatini on the Future of Dose-Dense Therapy in Ovarian Cancer

November 9th 2017

Paul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses the future of dose-dense therapy in ovarian cancer.

More Studies Needed to Improve Detection and Classification of Fallopian Tube Tumors

September 22nd 2017

Giampero (John) A. Martignetti, MD, PhD, explains that more large-size clinical trials need to be conducted to answer some of the burgeoning questions in the fallopian tube and ovarian cancer landscape.

Testing Beyond BRCA a Growing Approach in Ovarian Cancer Families

September 21st 2017

Ophira Ginsburg, MD, discusses hereditary ovarian cancer, the occasional reluctance in testing, multigene panels, and the understanding of variants of uncertain significance.

Dr. Levine on Immunotherapy for Endometrial Cancer

September 19th 2017

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone's Perlmutter Cancer Center, discusses immunotherapy for patients with endometrial cancer.

Expert Highlights Immunotherapy Potential in Ovarian Cancer

September 19th 2017

Dmitriy Zamarin, MD, PhD, discusses immunotherapy for patients with ovarian cancer.

Dr. Martignetti on Next-Generation Sequencing in Fallopian Tube Cancer

September 19th 2017

John A. Martignetti, MD, PhD, associate professor of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai, network director for the Laboratory for Translational Research at the Western Connecticut Health Network, discusses next-generation sequencing for patients with fallopian tube cancer.

PARP Inhibitors Have Potential to Benefit Larger Patient Populations in Ovarian Cancer

September 19th 2017

Bhavana Pothuri, MD, discusses the available PARP inhibitors and ongoing trials further investigating these agents in ovarian cancer.

Dr. Ginsburg on Genetic Testing in Ovarian Cancer Families

September 19th 2017

Ophira M. Ginsburg, MSc, MD, FRCPC, director of the High-Risk Cancer Program, Perlmutter Cancer Center at NYU Langone Medical Center, discusses the importance of genetic testing in ovarian cancer families.

Dr. Dottino on Molecular Detection of Recurrent Ovarian Cancer

September 18th 2017

Peter R. Dottino, MD, professor of obstetrics, gynecology and reproductive science, Mount Sinai Hospital, discusses molecular techniques used to determine ovarian cancer following treatment with chemotherapy.

Precision Medicine Rapidly Being Incorporated Into Ovarian Cancer Care

September 18th 2017

Douglas A. Levine, MD, shared his insight on how the ovarian cancer landscape has developed a more personalized treatment approach.